Fine mapping of the uterine leiomyoma locus on 1q43 close to a IncRNA in the RGS7-FH interval

Brahim Aissani1, Kui Zhang2, Arjen R Mensenkamp3,*, Fred H Menko4,* and Howard W Wiener1

1Department of Epidemiology, R217J, and 2Department of Biostatistics, School of Public Health, University of Alabama at Birmingham, 1665 University Boulevard, Birmingham, Alabama 35294-0022, USA
3Department of Human Genetics, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands
4Netherlands Cancer Institute, Amsterdam, The Netherlands
*on behalf of the Dutch HLRCC Working Group

Abstract

Mutations in fumarate hydratase (FH) on chromosome 1q43 cause a rare cancer syndrome, hereditary leiomyomatosis and renal cell cancer (HLRCC), but are rare in nonsyndromic and common uterine leiomyoma (UL) or fibroids. Studies suggested that variants in FH or in a linked gene may also predispose to UL. We re-sequenced 2.3 Mb of DNA spanning FH in 96 UL cases and controls from the multiethnic NIEHS-uterine fibroid study, and in 18 HLRCC-associated UL probands from European families then selected 221 informative SNPs for follow-up genotyping. We report promising susceptibility associations with UL peaking at rs78220092 (P = 7.0 × 10⁻⁷) in the RGS7-FH interval in African Americans. In race-combined analyses and in meta-analyses (n = 916), we identified promising associations with risk peaking upstream of a non-protein coding RNA (IncRNA) locus located in the RGS7-FH interval closer to RGS7, and associations with tumor size peaking in the distal phospholipase D family, member 5 (PLD5) gene at rs2654879 (P = 1.7 × 10⁻⁴). We corroborated previously reported FH mutations in nine out of the 18 HLRCC-associated UL cases and identified two missense mutations in FH in only two nonsyndromic UL cases and one control. Our fine association mapping and integration of existing gene profiling data showing upregulated expression of the IncRNA and downregulation of PLD5 in fibroids, as compared to matched myometrium, suggest a potential role of this genomic region in UL pathogenesis. While the identified variations at 1q43 represent a potential risk locus for UL, future replication analyses are required to substantiate our observation.

Key Words
- HLRCC
- uterine fibroids
- FH
- fumarate hydratase
- RGS7
- PLD5

Introduction

Uterine leiomyoma (UL) are benign neoplasms that arise from the smooth muscle cells of the uterus. Despite their benign nature, UL are responsible for significant gynecologic morbidities including excessive bleeding, pelvic pain, urinary incontinence, infertility, and pregnancy complications (Stewart 2001, Walker & Stewart 2005). As a consequence of this morbidity, uterine fibroids are the primary indication for hysterectomy, with an incidence rate of hysterectomies of 5.5 per 1000 women in the United States (Farquhar & Steiner 2002) and accounting for about $9.4 billion of public health burden. Cumulative exposure to estrogen is believed to be a major etiologic factor (Andersen...
1996) and factors that may influence the hormonal milieu, such as obesity, are also believed to be associated with risk (Schwartz et al. 2000). Clearly established risk factors are age (increasing risk with increasing premenopausal age), menopause (risk decreases with menopause) and African American (AA) ethnicity (higher risk compared with that of non-Hispanic Whites) (Baird et al. 2003).

Several lines of evidence for a genetic basis of UL have been demonstrated in familial aggregation and twin studies (Kurbanova et al. 1989, Vikhlyaeva et al. 1995, Luoto et al. 2000, Sato et al. 2002, Van Voorhis et al. 2002). Candidate susceptibility genes have emerged from genome-wide association studies (GWAS) (Cha et al. 2011, Eggert et al. 2012), mapping by admixture linkage disequilibrium (MALD) studies in AAs of signals for UL (Wise et al. 2012, Zhang et al. 2015) and from our candidate gene approach implicating genes encoding components of the extracellular matrix (Aissani et al. 2015). Studies conducted in Biorepository at Vanderbilt University study (BioVu) and right from the start study (RFTS) reported replications of GWAS findings in the Japanese population (Cha et al. 2011) of candidate trinucleotide repeat containing 6B (TNRC6B) and blocked early in transport 1 homolog (ZAT) genes (Edwards et al. 2013a,b). Exome sequencing in 18 fibroids and matched normal myometria has implicated the gene encoding the mediator complex subunit 12 (MED12) in UL (Makinen et al. 2011). Further examinations of whole genome sequences and gene-expression profiling in a set of 38 fibroids and matched myometria led to the hypothesis that a chromothripsis-like event drives the pathogenesis of UL leading to translocations of HMG2A and RAD51B, and to other chromosomal aberrations including the collagen COL4A5-COL4A6 locus (Mehine et al. 2013). In contrast to these somatic mutations, germline mutations associated with UL were observed in the gene encoding the Krebs cycle enzyme fumarate hydratase (FH) in hereditary leiomyomatosis and renal cell carcinoma (HLRCC; OMIM 150800), a rare and dominantly-transmitted Mendelian syndrome (Tomlinson et al. 2001, Launonen et al. 2002, Tomlinson et al. 2003). Of the enrolled premenopausal women, 1045 (93%) were African American (AA) ethnicity (higher risk compared with that of non-Hispanic Whites) (Baird et al. 2003, Aissani et al. 2015) and report

However, we could not assess whether regulator of G-protein signaling 7 (RGS7), FH or any of the characterized gene loci located between them was the true target in UL because the association with UL peaked in the RGS7-FH interval. The aim of the present study was to: i) refine the location of the candidate gene(s) for risk and size of UL; ii) test whether FH is also mutated in UL but a presumably marked allele heterogeneity at this locus, similar to that observed in HLRCC (Tomlinson et al. 2002, Bayley et al. 2008) precluded detection of associations; and iii) test for the presence of alternative susceptibility loci in the FH region that might associate with UL and would explain up to 40% of women with HLRCC-associated UL that do not carry mutations in FH (Tomlinson et al. 2002).

To this end, we re-sequenced 2.3 Mb across FH in a subset of NIEHS-UFS UL cases and controls (n=96) and in 18 probands from Dutch families segregating HLRCC, and identified candidate single nucleotide polymorphisms (SNPs) for follow-up genotyping in the remaining NIEHS-UFS sample (n=820). We report new association data in NIEHS-UFS implicating a large intergenic non-coding RNA (IncRNA) located between RGS7 and FH in nonsyndromic UL. We confirm previously reported FH mutations in nine of the 18 re-sequenced HLRCC probands (Smit et al. 2011) and report FH mutations in only two UL cases and also in one UL-free control.

Material and methods

Study population

Detailed characteristics of the study population have been reported (Baird et al. 2003, Aissani et al. 2013). Briefly, a random sample of women, aged 35–51 years, was selected from a computerized list of members of a prepaid urban health plan for enrollment in the NIEHS-UFS (Baird et al. 2003). Of the enrolled premenopausal women, 1045 (93%) had ultrasound examinations and available DNA specimens self-identified as having an AA (n=574), non-Hispanic European American (EA, n=394) or other (n=77) ethnic background. The NIEHS-UFS and the present sub-study were approved by the Human Subjects Review Boards at the NIH, George Washington University and University of Alabama at Birmingham respectively. Participants gave written informed consent in accordance with these Review Boards.

Ascertainment

Fibroid status was assessed by ultrasound screening at baseline or by medical record review in about 84 and 90%
of the AA and EA participants respectively. For women who had a pelvic ultrasound examination recently at a health plan (24.7% in AA and 12.1% in EA), the radiology records from that examination were used to assess fibroid status. The remaining premenopausal participants (59.5% in AA and 76.8% in EA) were asked to have a pelvic ultrasound examination at a primary care site. Women for whom neither ultrasound nor medical record review could be conducted were excluded. Both a transabdominal and a transvaginal ultrasound examination were performed. The abdominal portion evaluated fibroid change arising from the upper uterus that would not be readily seen with the transvaginal approach alone. Tumor size was classified in three categories of size (small, medium and large) measured by the diameter of the tumors (S ≤ 2 cm, 2 < M < 4 cm, L ≥ 4 cm). For participants diagnosed with multiple tumors, the largest tumor determined the size category.

Covariates
The covariates included age, age at menarche, parity after age 25 (earlier births were not significantly related to fibroid development in the NIEHS-UFS) (Baird et al. 2003), BMI and physical activity.

Family recruitment
Probands and family members of HLRCC families visited outpatient clinics throughout The Netherlands. DNA was sent to the Genome Diagnostics Laboratory at the Radboud University Medical Center in Nijmegen (The Netherlands). FH gene analysis was performed as previously described (Smit et al. 2011). All patients approved the anonymous use of their DNA, in accordance with Dutch law.

Genotyping and sequencing
DNA preparation DNA was extracted from blood samples using the QIAAMP DNA Mini Kit (QIagen) procedure and isolated DNA has undergone purification prior to quantification by the PicoGreen assay (Invitrogen).

Next-generation sequencing Having observed several peaks of association with risk and tumor size in the initial study (Aissani et al. 2013), we opted for a two-stage approach (re-sequencing and follow-up genotyping) to fully investigate DNA sequence variation in the target genomic region. Illumina HiSeq2000 sequencing system (Illumina, Inc., San Diego, CA, USA) was used to re-sequence about 2.3 Mb of DNA (from downstream of RG57 to upstream of phospholipase D family, member 5 (PLD5) spanning the FH locus in a subset of 96 NIEHS-UFS samples representative of each of the affection status (UL cases or controls), BMI categories and ethnic groups (EA and AA). Eighteen probands from Dutch families with confirmed or suspected HLRCC and two female relatives with no HLRCC-associated UL were also selected for re-sequencing.

Genotyping We selected a set of 264 SNPs for follow-up genotyping consisting of 45 custom assays (new SNPs identified through re-sequencing) and 219 validated SNP assays from dbSNP. The selection was based on different criteria including but not limited to the statistical significance (analysis of combined AA and EA cases and controls), minor allele frequency (MAF > 5%), SNP location in gene functional regions (for intragenic SNPs, further selection was based on linkage disequilibrium with associated SNPs in the initial study (Aissani et al. 2013)) and SNP assay designability. We used the Illumina GoldenGate platform (Illumina, Inc.) to genotype 820 NIEHS-UFS (477 AA and 343 EA) samples. Reliability in genotyping data was assessed by inclusion of blind duplicates (two duplicates per 96-well plates) and HapMap positive control samples (four controls per 96-well plates) as required by the Genetic Resources Core Facility of the Johns Hopkins University.

Statistical analysis
Quality control A call rate of 95% and a concordance rate of 100% between duplicates were assigned as quality control thresholds of the genotyping data. Prior to their inclusion in the analysis, SNP calls were examined separately in each ethnic group and affection status for adherence to Hardy–Weinberg equilibrium (HWE) using the Pearson’s χ² test and SNPs showing significant deviation (P < 0.01) from HWE in the controls were excluded.

Association testing Model-free Discriminant Analysis of Principal Components (DAPC) (Jombart et al. 2010) based on a total set of 4363 SNPs from over the genome was used in a previous study to define clusters of genetically related individuals in NIEHS-UFS (Aissani et al. 2013). Logistic regression models adjusted for covariates were fitted to the data to evaluate the association between SNP genotypes and the risk for UL modeled as a dichotomous outcome (case and control design) or as polytomous outcome in either case–control thresholds of the genotyping data. Prior to their inclusion in the analysis, SNP calls were examined separately in each ethnic group and affection status for adherence to Hardy–Weinberg equilibrium (HWE) using the Pearson’s χ² test and SNPs showing significant deviation (P < 0.01) from HWE in the controls were excluded.
M vs L) or in a design that also included controls (four-level outcome) with no tumor (N) (N vs S, M; L; N, S vs M, L; N, S, M vs L). For the polytomous outcome, P value is reported only for the SNPs that met the assumption of proportional odds. In logistic regression modeling, the most frequent homozygous genotype in the controls (or category with the lowest level in proportional odds models) served as the reference genotype. The likelihood ratio test provided estimates of the statistical significance for each univariate SNP test as two-sided P values. Bonferroni correction was used to adjust for multiple testing and P values of less than the threshold (0.05/number of tested SNPs) in race-stratified analyses or in pooled analyses were deemed to be statistically significant. In pooled analyses, the logistic regression models were further adjusted for the SNP by race interaction term. Meta-analyses were conducted using random-effect variance and DerSimonian-Laird estimator (DerSimonian & Laird 1986) in the Metafor package (Viechtbauer 2010).

In contrast to HLRCC, which is inherited in an autosomal-dominant mode, there is no a priori knowledge on the genetic model underlying UL. Therefore, analyses were conducted under dominant and additive genetic models as well as in genotypic tests (model-free 2-d.f. test) but only data from additive models are shown.

Gene expression analysis  We used publicly available expression data from a study of uterine fibroids (Guo et al. 2015) to evaluate the functional impact of identified candidate loci. We retrieved raw expression data for IncRNA and cis mRNAs in uterine fibroids and matched myometrium from the EMBL-EBI Array Express website (http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-52618/files/). The raw data contained expression of 62,738 probes from five groups of matched samples (five myometrium, five small fibroids and five large fibroids). Log2 transformation followed by quantile normalization (Bolstad et al. 2003) were used to normalize the raw data. The three probes corresponding to the candidate IncRNA, FH, and RGS7 were identified through BLAST and their normalized expression levels were used for the calculation of Pearson’s and Spearman’s correlation coefficients with R (http://www.r-project.org/) for co-regulated IncRNA-mRNA expressions.

Results

Quality control

A subset of 43 (16%) SNPs consisting both of custom and validated SNP assays have failed genotyping. Among the remaining SNPs, the call rate was 99.7% and the concordance rate among duplicates was 100%. A possible explanation to these genotyping failures is the proximity among SNPs, which can hinder the multiplex GoldenGate assay even by observing the minimal inter-SNP distance of 60 bp recommended by the manufacturer.

Next-generation sequencing and FH mutation analysis

A minimum sequencing depth of 50× was achieved and re-sequencing failed only for a single NIEHS-UFS sample. A total of 21,078 SNPs (on average 1 SNP/109 bp) including a subset of 253 gene regulatory and coding SNPs was identified. The higher polymorphism frequency compared to the 1000 genome project can be explained by the higher coverage depth in our next-generation sequencing (NGS) assay (50× vs 4×). We observed a total of 154 SNPs in the 22 kb-long FH gene (21 variants in coding and regulatory regions) in 113 quality control samples (93 NIEHS-UFS and 20 HLRCC samples) and confirmed the presence of FH mutations (Table 1) in nine of the 18 tested HLRCC probands as previously reported (Smit et al. 2011). The proband who carried FH mutation c.952C>T (p.His318Tyr) presented cutaneous leiomyoma and no UL.

In nonsyndromic UL, two missense mutations in FH exon 1 (c.53C>T and c.55G>T) were found in two UL cases and one control of AA descent (Table 1). Mutation c.55G>T (p.Ala19Ser) occurred in a single case out of 24 re-sequenced UL cases of AA descent (MAF = 0.021 among AA cases and a MAF = 0.0054 in the entire re-sequenced AA and EA case and control samples). Mutation c.53C>T (p.Pro18Leu) occurred in 2% of the AA cases and 1.1% in the entire re-sequenced sample.

Follow-up association mapping in race-stratified analysis

Association of 221 post-NGS and QC-filtered SNPs with the risk of UL was evaluated in additive models separately in the AA and EA groups (Supplementary Figure S1, see section on supplementary data given at the end of this article). The results showed an association (P = 6.5×10⁻⁴) at the intronic variant rs35914368 in the S’ end of RGS7 and statistically significant association (P = 7.0×10⁻⁵) at rs78220092 in the RGS7-FH intergenic region in the AA group. The most significantly associated rs78220092 SNP has a MAF of about 0.14 in the AA group and is rare (<1%) in EA.

In proportional odds models, the associations with tumor size were marginal (Supplementary Figure S2) and reached the highest statistical significance at rs28627534.
Table 1 Mutational analysis of the fumarate hydratase gene in syndromic and nonsyndromic uterine leiomyoma

<table>
<thead>
<tr>
<th>ID</th>
<th>Study</th>
<th>Race</th>
<th>Sex</th>
<th>Affection status</th>
<th>HLRCC</th>
<th>SNP</th>
<th>Position (bp)</th>
<th>Allele</th>
<th>DNA change</th>
<th>Protein change</th>
<th>MAF</th>
</tr>
</thead>
<tbody>
<tr>
<td>3633</td>
<td>HLRCC</td>
<td>EUR</td>
<td>2</td>
<td>1</td>
<td>UL</td>
<td>C</td>
<td>241 665 769</td>
<td>C</td>
<td>c.1210G&gt;T</td>
<td>p.Gln404X</td>
<td>0.002</td>
</tr>
<tr>
<td>3738</td>
<td>HLRCC</td>
<td>EUR</td>
<td>2</td>
<td>1</td>
<td>CL</td>
<td>A</td>
<td>241 665 769</td>
<td>A</td>
<td>c.1210G&gt;T</td>
<td>p.Gln404X</td>
<td>0.002</td>
</tr>
<tr>
<td>6229</td>
<td>HLRCC</td>
<td>EUR</td>
<td>2</td>
<td>1</td>
<td>RCC</td>
<td>C</td>
<td>241 665 835</td>
<td>C</td>
<td>c.1144A&gt;G</td>
<td>p.Gly374Ser</td>
<td>0.002</td>
</tr>
<tr>
<td>7551</td>
<td>HLRCC</td>
<td>EUR</td>
<td>2</td>
<td>1</td>
<td>UL</td>
<td>C</td>
<td>241 667 448</td>
<td>T</td>
<td>c.1002T&gt;G</td>
<td>p.Ser334Arg</td>
<td>0.002</td>
</tr>
<tr>
<td>4760</td>
<td>HLRCC</td>
<td>EUR</td>
<td>2</td>
<td>1</td>
<td>CL</td>
<td>C</td>
<td>241 667 448</td>
<td>A</td>
<td>c.1002T&gt;G</td>
<td>p.Ser334Arg</td>
<td>0.002</td>
</tr>
<tr>
<td>1028</td>
<td>HLRCC</td>
<td>EUR</td>
<td>2</td>
<td>0</td>
<td>UL</td>
<td>A</td>
<td>241 667 498</td>
<td>G</td>
<td>c.952C&gt;T</td>
<td>p.His318Ty</td>
<td>0.002</td>
</tr>
<tr>
<td>2542</td>
<td>HLRCC</td>
<td>EUR</td>
<td>2</td>
<td>1</td>
<td>CL</td>
<td>C</td>
<td>241 669 383</td>
<td>C</td>
<td>c.824G&gt;A</td>
<td>p.Gly275Glu</td>
<td>0.002</td>
</tr>
<tr>
<td>4856</td>
<td>HLRCC</td>
<td>EUR</td>
<td>2</td>
<td>1</td>
<td>RCC</td>
<td>C</td>
<td>241 669 383</td>
<td>C</td>
<td>c.824G&gt;A</td>
<td>p.Gly275Glu</td>
<td>0.002</td>
</tr>
<tr>
<td>3975</td>
<td>HLRCC</td>
<td>EUR</td>
<td>2</td>
<td>1</td>
<td>UL</td>
<td>C</td>
<td>241 671 943</td>
<td>C</td>
<td>c.698G&gt;A</td>
<td>p.Arg233His</td>
<td>0.002</td>
</tr>
<tr>
<td>10755</td>
<td>HLRCC</td>
<td>EUR</td>
<td>2</td>
<td>1</td>
<td>CL</td>
<td>C</td>
<td>241 671 943</td>
<td>C</td>
<td>c.698G&gt;A</td>
<td>p.Arg233His</td>
<td>0.002</td>
</tr>
<tr>
<td>796</td>
<td>NIEHS-UFS</td>
<td>AA</td>
<td>2</td>
<td>1</td>
<td>UL</td>
<td>C</td>
<td>241 682 968</td>
<td>C</td>
<td>c.55G&gt;T</td>
<td>p.Ala19Ser</td>
<td>0.002</td>
</tr>
<tr>
<td>629</td>
<td>NIEHS-UFS</td>
<td>AA</td>
<td>2</td>
<td>1</td>
<td>UL</td>
<td>C</td>
<td>241 682 970</td>
<td>C</td>
<td>c.53C&gt;T</td>
<td>p.Pro18Leu</td>
<td>0.002</td>
</tr>
<tr>
<td>1065</td>
<td>NIEHS-UFS</td>
<td>AA</td>
<td>2</td>
<td>0</td>
<td>UL</td>
<td>C</td>
<td>241 682 970</td>
<td>G</td>
<td>c.53C&gt;T</td>
<td>p.Pro18Leu</td>
<td>0.002</td>
</tr>
</tbody>
</table>

HLRCC, hereditary leiomyomatosis and renal cell cancer; NIEHS-UFS, National Institute of Environmental Health Science uterine fibroid study; EUR, European; AA, African American; UL, uterine leiomyoma; CL, cutaneous and leiomyoma; RCC, renal cell cancer; SNP, single nucleotide polymorphism; ref, reference allele; alt, alternative allele; MAF, minor allele frequency. All positions are according to the human genome assembly 19 (GRCh37/hg19).

*Syndromic or non-syndromic uterine leiomyoma (1 = affected; 0 = unaffected).
expression (Supplementary Figures S4 and S5, see section on supplementary data given at the end of this article) in blood (Heinzen et al. 2008). No eQTL information was available in the SNPexpress database for the other candidate SNPs listed in Table 2 except for rs4660080, which showed no significant association with either RGS7 or FH, and for the distal SNPs rs2654879 and rs6429360, which were not associated with PLD5 expression.

Using published expression data (Guo et al. 2014), we tested whether regulation (up- or down-regulation) of the target lncRNA expression occurs in fibroids compared to matched myometrium. The results showed a threefold increase (Log2 fold change $Z_{1.62}$) in the lncRNA expression in the large fibroids as compared to the myometrium ($P_{0.02}$) (Supplementary Table S2). A marginal difference ($P_{0.09}$) in the lncRNA expression was observed between large and small tumors and no significant or marginal difference was observed between small tumors and myometrium, suggesting possible effects of this lncRNA on tumor size.

Compared to UC.10, a well-studied lncRNA overlapping ADAM metallopeptidase domain 12 (ADMA12) and reported to be significantly upregulated ($P_{5.2 \times 10^{-5}}$) in uterine fibroids, and to some extent to the target lncRNA in the present study, no significant change in gene expression was seen for the putative cis-regulated FH and RGS7 genes.

Furthermore, we tested whether the lncRNA and the cis mRNA expressions were co-regulated and observed a moderate correlation in a global test (all tissues considered) for the lncRNA-RGS7 pair (Pearson’s $r_{0.52}$ and Spearman’s $r_{0.58}$) and for CU.10-ADAM12 ($r_{0.61}$ and $r_{0.51}$) but not for lncRNA-FH (Supplementary Table S3, see section on supplementary data given at the end of this article). Higher correlations were further seen for the lncRNA-RGS7 pair when the analysis was restricted to the small and large fibroids ($r_{0.58}$ and $r_{0.71}$).

Association of chromosome 1q43 SNPs with tumor size

The association with tumor size peaked at the risk-associated SNP rs2341938 ($P_{5.5 \times 10^{-5}}$) when a four-level response variable (no tumor, small, medium and large) was modeled (Fig. 1). In a case-only design (small, medium and large), the strongest associations was observed in intron 2 of PLD5 at rs2654879 ($P_{1.7 \times 10^{-4}}$) in the combined analysis (Table 2 and Fig. 1). In meta-analysis, the association peaked at the
Table 2  List of chromosome 1q43 single nucleotide polymorphisms associated with risk or size of uterine leiomyoma in the NIEHS uterine fibroid study

<table>
<thead>
<tr>
<th>SNP</th>
<th>Inter SNP distance (bp)</th>
<th>Minor allele frequency</th>
<th>Gene/function</th>
<th>Location</th>
<th>eQTL-associated genes, P</th>
<th>Pooled sample analysis, P</th>
<th>Meta-analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>EA</td>
<td>AA</td>
<td></td>
<td></td>
<td>Risk</td>
<td>Tumor size</td>
</tr>
<tr>
<td>rs4660080A&gt;G</td>
<td>-</td>
<td>0.44</td>
<td>0.49</td>
<td>RSβ7- Inc-RNA</td>
<td>Intergenic</td>
<td>2.1 × 10^{-4}</td>
<td>9.4 × 10^{-5}</td>
</tr>
<tr>
<td>rs2341938G&gt;A</td>
<td>3958</td>
<td>0.44</td>
<td>0.46</td>
<td>RSβ7- Inc-RNA</td>
<td>Intergenic</td>
<td>1.6 × 10^{-4}</td>
<td>5.5 × 10^{-5}</td>
</tr>
<tr>
<td>rs78220092C&gt;A</td>
<td>1829</td>
<td>0.006</td>
<td>0.14</td>
<td>RSβ7- Inc-RNA</td>
<td>NA</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>rs1891129C&gt;T</td>
<td>38 107</td>
<td>0.46</td>
<td>0.49</td>
<td>Inc-RNA</td>
<td>Upstream</td>
<td>FH, 0.001</td>
<td>1.7 × 10^{-2}</td>
</tr>
<tr>
<td>rs28627534G&gt;A</td>
<td>569 850</td>
<td>0.46</td>
<td>0.46</td>
<td>MAP1L3C</td>
<td>Downstream</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>rs3169121T&gt;C</td>
<td>278 911</td>
<td>0.00</td>
<td>0.03</td>
<td>PLD5</td>
<td>Intron</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>rs2654879T&gt;C</td>
<td>165 158</td>
<td>0.45</td>
<td>0.31</td>
<td>PLD5</td>
<td>Intron</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>rs6429360G&gt;A</td>
<td>53 876</td>
<td>0.05</td>
<td>0.41</td>
<td>PLD5</td>
<td>Intron</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

SNP, single nucleotide polymorphism; EA, European American; AA, African American; eQTL, expression quantitative trait locus; P-het, P value for the test of heterogeneity; Inc-RNA, large intergenic non-coding RNA; RSβ7, regulator of G-protein signaling 7; FH, fumarate hydratase; MAP1L3C, microtubule-associated protein 1 light chain 3 gamma; PLD5, phospholipase D family, member S; –, not significant at P = 0.05 or that the assumption for proportional odds was not met; NA, non-apply (no information available). SNPs shown in bold are those that reached nearly or statistically significant association (Bonferroni-adjusted P < 0.05) with either risk or size of UL and in either race-stratified analyses, combined analyses or meta-analyses.

Discussion

The aim of the current study was to refine the location of a susceptibility locus for UL. A mutation of chromosome 1q43 containing FH, a gene mutated in HLRCC-associated UL but rarely in the common form of UL, was found in our initial study that pointed to putative susceptibility loci for UL. We noted the gene expression was, however, observed between small fibroids and matched myometrium (P = 0.409).
Risk of UL such as adiposity (Aissani et al. 2013) to unequivocally assess the spectrum of mutations in the entire NIEHS-UFS sample is worth an undertaking with unknown pathogenicity, screening for genomic region of susceptibility loci for UL (Gross et al. 2008), predisposing for prostate cancer (PCaP; OMIM 602759) (Berthon et al. 1998) and for factors affecting the risk of UL such as adiposity (Aissani et al. 2006) and serum level of sex hormone-binding globulin (SHBG) (Ukkola et al. 2004), possibly because genetic variants influencing the transcription, sequence or structure of the IncRNA may interfere with the expression of the target cis gene. The sole gene profiling study to date that examined the expression of IncRNAs in fibroids provided the first functional evidence for the potential implication of this genomic region in UL. While the data of the gene profiling study are supportive of our fine mapping of the putative UL susceptibility locus to the RGS7-FH interval, they are not consistent with FH expression being regulated by the IncRNA.

The possibility that the association signal upstream of the target IncRNA overlaps a regulatory region with cis effects on the IncRNA expression and the target cis mRNA cannot be excluded. Several examples of co-regulated IncRNA and protein-coding loci by the same cis-rSNP, the so-called enhancer RNA (eRNA), have been reported (Almlof et al. 2014). The role of these eRNAs in mediating the function of the enhancer in directing basal gene expression was demonstrated in a recent study for the distal enhancer of the gonadotropin hormone α-subunit gene (Pnueli et al. 2015).

Collectively, the results of the eQTL study in blood from SNPExpress (Heinzen et al. 2008), the IncRNA and cis-coding gene expression study in fibroids and matched myometrium (Guo et al. 2014) and the present study converge on the hypothesis that the IncRNA is a potential target in the pathogenesis of non-syndromic UL; however, the first available IncRNA expression data appear to be more supportive of RGS7 than FH as the target cis gene. Independent studies of co-regulated IncRNA and cis mRNA expressions in the RGS7-FH interval, as well as down-regulation of PLDS, in fibroids are needed to substantiate our observations.

Differential expression of non-coding RNA species and their target genes have been shown to associate with the risk of UL (Luo & Chegini 2008, Marsh et al. 2008, et al. 2002) (Supplementary Figure S6, see section on supplementary data given at the end of this article). Furthermore, a large-scale meta-analysis of GWAS also implicated this genomic region in age-at-menopause (Stolk et al. 2012), a known risk for UL (increasing risk with increasing age-at-menopause). Collectively, these and other independent observations (Aissani et al. 2013) led to our working hypothesis that an alternative susceptibility locus lies in the vicinity of FH and acts alone or in interaction with FH to increase the risk of UL in susceptible individuals (Aissani et al. 2013).

Fine mapping of the association signal near a lncRNA locus is consistent with our hypothesis for the implication of an alternative 1q43 gene in nonsyndromic UL because genetic variants influencing the transcription, sequence or structure of the lncRNA may interfere with the expression of the target cis gene. The sole gene profiling study to date that examined the expression of IncRNAs in fibroids provided the first functional evidence for the potential implication of this genomic region in UL. While the data of the gene profiling study are supportive of our fine mapping of the putative UL susceptibility locus to the RGS7-FH interval, they are not consistent with FH expression being regulated by the IncRNA.

Re-sequencing of the candidate genomic region in 18 probands from European families with suspected or confirmed HLRCC confirmed the presence of FH mutations in nine of them as previously reported (Smit et al. 2011).

Our rationale for evaluating the relevance of the FH-linked region to the development of UL was motivated by early linkage studies suggesting the presence in this genomic region of susceptibility loci for UL (Gross et al. 2004), predisposing for prostate cancer (PCaP; OMIM 602759) (Berthon et al. 1998) and for factors affecting the risk of UL such as adiposity (Aissani et al. 2006) and serum level of sex hormone-binding globulin (SHBG) (Ukkola et al. 2015).
Zavadil et al. 2010, Georgieva et al. 2012) and tumor size (Wang et al. 2007). However, most of the RNA molecules reported to be differentially expressed in fibroids vs myometrium are microRNA (miRNA) species. lncRNAs form a specific group of non-coding RNAs (Woo & Kingston 2007) transcribed from ultraconserved intergenic regions and implicated in complex mechanisms of gene regulation such as epigenetic mechanisms (Mattick 2003, Costa 2008). Growing evidence for the implication of lncRNAs in tumorigenesis has been accumulating and, importantly, some of them have been shown to be significant predictors of tumor progression (Bussemakers et al. 1999, Ji et al. 2003, Yu et al. 2008, Gupta et al. 2010, Veltri 2014).

While several lines of evidence for the role of FH mutations in HLRCC have been reported, the exact mechanism of pathogenesis is still under study. The current paradigm invokes up-regulation of hypoxia-inducible factors (HIF) and hypoxia responsive genes in tumors with reduced expression of mitochondrial FH (Eng et al. 2003, Pollard et al. 2005, Ashrafian et al. 2010). However, the mechanism contributing to HIF activation (pseudo-hypoxic drive, increase in reactive oxygen species, defective apoptotic mechanism or anabolic drive resulting from accumulation of glycolytic intermediates) is still a debate. Our study failed to identify frequent FH mutations that would be consistent with the common nature of nonsyndromic UL but cannot exclude FH as a candidate target regulated by the associated lncRNA.

RGS7 and PLD5 are suspected adiposity genes (Aissani et al. 2006, Wang et al. 2011, Aissani 2014) that may indirectly affect tumor growth through changes in the hormonal milieu. For instance, by decreasing the serum level of SHBG, which may result in increased bioavailability of estrogen (Schwartz et al. 2000). The report of genetic linkage between this genomic region of chromosome 1q43 with the level of SHBG in the HERITAGE family study (Ukkola et al. 2002) may not be fortuitous. Nonetheless, co-localization of signals for several correlated traits and diseases (adiposity, UL, age-at-menopause, serum SHBG, predisposing for prostate cancer) to a genomic region overlapping the lncRNA locus may reflect complex linkage disequilibrium between 1q43 loci with significant effect size, pleiotropy or coordinated gene expression (Aissani 2014).

We have modeled tumor size as an ordinal variable with a three-level (case-only) or a four-level outcome variable that included UL-free controls. The design that includes the controls is important to test because misclassification of cases with small, ultrasound-undetectable tumors (<0.5 cm of diameter) as controls can be substantial (Baird et al. 2003), especially in cross-sectional studies. In contrast to the risk SNP rs2341938, rs2654879 and rs316912 SNPs associated only with tumor size and not with both outcomes. A possible explanation would be that the former SNP tags a null mutation while the latter tag variants affecting the level of gene expression.

Disentangling the genetic correlates of syndromic vs nonsyndromic UL in the studied genomic region on chromosome 1q43 is an important future undertaking to improve our understanding not only of UL pathogenesis but also of the genetic mechanisms underlying syndromic forms (rare Mendelian disease) and nonsyndromic (common diseases) counterparts of diseases in general.

Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/ERC-15-0208.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This work was supported by grant R01-HD064398 from the National Institute of Child Health and Human Development (NIH-NICHD) and the National Institute for Environmental Health Science (NIH-NIEHS).

Patient consent
All participants provided written informed consent, including permission to perform genetic analysis.

Ethics approval
All studies involved in this research received institutional review board approvals.

Author contribution statement
All listed authors have substantially contributed to the work. B Aissani, K Zhang and H W Wiener conceived and designed the experiments. A R Mensenkamp and F H Menko investigated HLRCC patients and contributed samples. H W Wiener analyzed the data; B Aissani and K Zhang provided analytical support. All authors contributed to the interpretation of the results. B Zhang drafted the manuscript and all authors reviewed/edited manuscript. All authors approved the final manuscript.

Acknowledgements
The authors are grateful to Dr Donna Day Baird, the principal investigator of the NIAMS Uterine Fibroid Study, for her support. The authors thank the women who participated to the NIAMS-UFS and members of the families
Recruited by the Dutch HLRCC Working Group for their valuable contribution to this research.

References


leio...cell. PNAS 98 3387–3392. (doi:10.1073/pnas.051633798)


Received in final form 9 June 2015
Accepted 15 June 2015
Made available online as an Accepted Preprint 25 June 2015